In advanced prostate cancer, when patients become resistant to first-line classical androgen deprivation therapy, alternative options, besides chemotherapy, do exist.Abiraterone and Enzalutamide are recently developed hormonal treatments which have demonstrated benefit in survival. Ian Tannock explains how to use these drugs and when chemotherapy should be recommended in castration-resistant prostate cancer patients.

Major Sponsors

AstraZeneca Bristol-Myers Squibb MSD Servier

Main Sponsors

Astellas Bayer Healthcare Boehringer Ingelheim Daiichi Sankyo ipsen Janssen Novartis Roche